HPV-Related Squamous Cell Carcinoma Clinical Trial
Official title:
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 & HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.
HB-201 and HB-202 are study drugs which are designed to train the body to recognize and fight substances found in HPV 16+ cancer. This trial studies the safety and anti-cancer effect of HB-201 and HB-202 in people. The trial is enrolling patients with metastatic/recurrent head and neck cancer who have not yet received treatment in this setting (1L, first line) and who are eligible to receive pembrolizumab as part of their standard of care. This trial is also enrolling patients with metastatic/recurrent head and neck who have received prior treatment in this setting (2L+, second and later line) who are eligible to receive pembrolizumab as part of their standard of care. Patients will receive the study drugs in addition to their pembrolizumab standard of care regimen. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
|
Phase 2 | |
| Withdrawn |
NCT05472220 -
Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05973487 -
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05686226 -
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
|
Phase 2 | |
| Recruiting |
NCT03795610 -
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05582590 -
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03107182 -
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05639972 -
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05608369 -
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
|
Phase 2 | |
| Recruiting |
NCT04369937 -
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT04900623 -
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
|
Phase 2 | |
| Recruiting |
NCT03423264 -
PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing
|
Phase 2 | |
| Recruiting |
NCT03786601 -
Postmenopausal Women With Vaginal Microbiota
|
||
| Recruiting |
NCT06016920 -
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04988074 -
Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
|
Phase 2 | |
| Recruiting |
NCT04979000 -
HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors
|
||
| Recruiting |
NCT03944915 -
De-Escalation Therapy for Human Papillomavirus Negative Disease
|
Phase 2 | |
| Recruiting |
NCT03895866 -
Persistent Cervical HPV Infection With Clearance and Vaginal Microbiota
|